Tiroid Nodülü Genomik Profillemesi: ThyroSeq Yeni-Nesil Dizinlemenin Klinik Karar Verme Üzerinde Güncel Rolü

Translated title of the contribution: Genomic profiling of thyroid nodules: Current role for ThyroSeq next-generation sequencing on clinical decision-making

Atil Kargi, Marcela Perez Bustamante, Seza Gulec

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

In recent years there has been an increased awareness of the genetic alterations underlying both benign and malignant neoplasms of the thyroid. Next-generation sequencing (NGS) is an emerging technology that allows for rapid detection of a large number of genetic mutations in thyroid fine-needle aspiration (FNA) specimens. NGS for targeted mutational analysis in thyroid tumors has been proposed as a tool to assist in the diagnosis of thyroid nodules with indeterminate FNA cytology. Results of genomic testing of thyroid nodules and thyroid cancers could also have prognostic implications and play a role in determining optimal treatment strategies including targeted therapies. We provide a critical review of existing studies assessing the performance of the ThyroSeq NGS test for the diagnosis and management of patients with thyroid nodules with indeterminate cytopathology and discuss the applicability of findings from these studies to clinical practice. While there are early indications to suggest a possible utility of data obtained from NGS to aid in prognostication and therapeutic decisionmaking in thyroid cancer, we recommend judicious use and cautious interpretation of such molecular testing until results of ongoing clinical trials become available. Lastly, we discuss recommendations provided from clinical practice guidelines regarding the use of mutation detection via NGS in the diagnostic evaluation of thyroid nodules.

Original languageTurkish
Pages (from-to)24-35
Number of pages12
JournalMolecular Imaging and Radionuclide Therapy
Volume26
DOIs
StatePublished - 2017

Fingerprint

Thyroid Nodule
Thyroid Gland
Fine Needle Biopsy
Thyroid Neoplasms
Mutation
Practice Guidelines
Cell Biology
Neoplasms
Therapeutics
Clinical Trials
Technology
Clinical Decision-Making

Keywords

  • Genomic profiling
  • Molecular testing
  • Next-generation sequencing
  • Thyroid cancer
  • Thyroid nodule
  • ThyroSeq

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Tiroid Nodülü Genomik Profillemesi : ThyroSeq Yeni-Nesil Dizinlemenin Klinik Karar Verme Üzerinde Güncel Rolü. / Kargi, Atil; Bustamante, Marcela Perez; Gulec, Seza.

In: Molecular Imaging and Radionuclide Therapy, Vol. 26, 2017, p. 24-35.

Research output: Contribution to journalReview article

@article{2123e9c7759541869eceff8b685cd1c8,
title = "Tiroid Nod{\"u}l{\"u} Genomik Profillemesi: ThyroSeq Yeni-Nesil Dizinlemenin Klinik Karar Verme {\"U}zerinde G{\"u}ncel Rol{\"u}",
abstract = "In recent years there has been an increased awareness of the genetic alterations underlying both benign and malignant neoplasms of the thyroid. Next-generation sequencing (NGS) is an emerging technology that allows for rapid detection of a large number of genetic mutations in thyroid fine-needle aspiration (FNA) specimens. NGS for targeted mutational analysis in thyroid tumors has been proposed as a tool to assist in the diagnosis of thyroid nodules with indeterminate FNA cytology. Results of genomic testing of thyroid nodules and thyroid cancers could also have prognostic implications and play a role in determining optimal treatment strategies including targeted therapies. We provide a critical review of existing studies assessing the performance of the ThyroSeq NGS test for the diagnosis and management of patients with thyroid nodules with indeterminate cytopathology and discuss the applicability of findings from these studies to clinical practice. While there are early indications to suggest a possible utility of data obtained from NGS to aid in prognostication and therapeutic decisionmaking in thyroid cancer, we recommend judicious use and cautious interpretation of such molecular testing until results of ongoing clinical trials become available. Lastly, we discuss recommendations provided from clinical practice guidelines regarding the use of mutation detection via NGS in the diagnostic evaluation of thyroid nodules.",
keywords = "Genomic profiling, Molecular testing, Next-generation sequencing, Thyroid cancer, Thyroid nodule, ThyroSeq",
author = "Atil Kargi and Bustamante, {Marcela Perez} and Seza Gulec",
year = "2017",
doi = "10.4274/2017.26.suppl.04",
language = "Turkish",
volume = "26",
pages = "24--35",
journal = "Molecular Imaging and Radionuclide Therapy",
issn = "2146-1414",
publisher = "Galenos Yayinevi",

}

TY - JOUR

T1 - Tiroid Nodülü Genomik Profillemesi

T2 - ThyroSeq Yeni-Nesil Dizinlemenin Klinik Karar Verme Üzerinde Güncel Rolü

AU - Kargi, Atil

AU - Bustamante, Marcela Perez

AU - Gulec, Seza

PY - 2017

Y1 - 2017

N2 - In recent years there has been an increased awareness of the genetic alterations underlying both benign and malignant neoplasms of the thyroid. Next-generation sequencing (NGS) is an emerging technology that allows for rapid detection of a large number of genetic mutations in thyroid fine-needle aspiration (FNA) specimens. NGS for targeted mutational analysis in thyroid tumors has been proposed as a tool to assist in the diagnosis of thyroid nodules with indeterminate FNA cytology. Results of genomic testing of thyroid nodules and thyroid cancers could also have prognostic implications and play a role in determining optimal treatment strategies including targeted therapies. We provide a critical review of existing studies assessing the performance of the ThyroSeq NGS test for the diagnosis and management of patients with thyroid nodules with indeterminate cytopathology and discuss the applicability of findings from these studies to clinical practice. While there are early indications to suggest a possible utility of data obtained from NGS to aid in prognostication and therapeutic decisionmaking in thyroid cancer, we recommend judicious use and cautious interpretation of such molecular testing until results of ongoing clinical trials become available. Lastly, we discuss recommendations provided from clinical practice guidelines regarding the use of mutation detection via NGS in the diagnostic evaluation of thyroid nodules.

AB - In recent years there has been an increased awareness of the genetic alterations underlying both benign and malignant neoplasms of the thyroid. Next-generation sequencing (NGS) is an emerging technology that allows for rapid detection of a large number of genetic mutations in thyroid fine-needle aspiration (FNA) specimens. NGS for targeted mutational analysis in thyroid tumors has been proposed as a tool to assist in the diagnosis of thyroid nodules with indeterminate FNA cytology. Results of genomic testing of thyroid nodules and thyroid cancers could also have prognostic implications and play a role in determining optimal treatment strategies including targeted therapies. We provide a critical review of existing studies assessing the performance of the ThyroSeq NGS test for the diagnosis and management of patients with thyroid nodules with indeterminate cytopathology and discuss the applicability of findings from these studies to clinical practice. While there are early indications to suggest a possible utility of data obtained from NGS to aid in prognostication and therapeutic decisionmaking in thyroid cancer, we recommend judicious use and cautious interpretation of such molecular testing until results of ongoing clinical trials become available. Lastly, we discuss recommendations provided from clinical practice guidelines regarding the use of mutation detection via NGS in the diagnostic evaluation of thyroid nodules.

KW - Genomic profiling

KW - Molecular testing

KW - Next-generation sequencing

KW - Thyroid cancer

KW - Thyroid nodule

KW - ThyroSeq

UR - http://www.scopus.com/inward/record.url?scp=85026847101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026847101&partnerID=8YFLogxK

U2 - 10.4274/2017.26.suppl.04

DO - 10.4274/2017.26.suppl.04

M3 - Review article

AN - SCOPUS:85026847101

VL - 26

SP - 24

EP - 35

JO - Molecular Imaging and Radionuclide Therapy

JF - Molecular Imaging and Radionuclide Therapy

SN - 2146-1414

ER -